Baker Tilly Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Baker Tilly Wealth Management's BMY Position: Q2 2026 in Review
Baker Tilly Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 6.5% in Q2 2026, selling an estimated $20.7K and leaving 5,164 shares worth $298K. The position accounts for 0.06% of the portfolio, ranked #218.
Baker Tilly Wealth Management first reported a position in BMY in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.42M in Q2 2022. 879 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Baker Tilly Wealth Management held 5,164 shares of Bristol-Myers Squibb worth $298K as of Q2 2026.
- Baker Tilly Wealth Management sold 360 Bristol-Myers Squibb shares in Q2 2026, an estimated $20.7K.
- Bristol-Myers Squibb made up 0.06% of Baker Tilly Wealth Management's portfolio in Q2 2026, its #218 holding.
- Baker Tilly Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 23 quarters since.
- Baker Tilly Wealth Management's Bristol-Myers Squibb position peaked at $1.42M in Q2 2022.
- 879 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Baker Tilly Wealth Management's 13F filing for Q2 2026, filed 17 Jul 2026.